Skip to main content

Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study

Cancer Chemotherapy and Pharmacology volume 27, pages 389–393 (1991)Cite this article

Summary

In a pilot study, 18 patients with advanced ovarian cancer were evaluated for tolerance and response to a combination treatment with a fixed dose of carboplatin (350 mg/m2 given i.v. on day 1) and escalated doses of etoposide (70–130 mg/m2 daily given i.v. on days 1–3) as first-line chemotherapy. The maximum tolerated dose of etoposide was 130 mg/m2 when given i.v. on days 1–3 in combination with 350 mg/m2 carboplatin given i.v. every 4 weeks. At these dose levels, bone marrow toxicity was manageable and did not appear to be cumulative. In all, 12 objective responses, including 9 complete responses (CRs) and 3 partial responses (PRs), were achieved in 18 patients; 6 of the 9 CRs were confirmed as pathological CRs by second-look surgery.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR (1987) A comparison of the toxicity and efficacy of cisplatin (CDDP) and carboplatin (JM8) in advanced ovarian cancer. Abstract 785, Proceedings of the 4th European Conference of Clinical Oncology, Madrid 207

  2. Anderson H, Wagstaff J, Crowther D, Swindell R, Lind MJ, McGregor J, Timms MS, Brown D, Palmer P (1988) Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 24: 1471

    Google Scholar 

  3. Atassi G, Kenis Y, Dumont P, Rozencweig M (1983) Animal screening of new platinum derivatives — studies with single agents and combinations. Abstract 27, Proceedings of the 4th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brüssel

  4. Barker GH, Wiltshaw E (1981) Randomized trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil and doxorubicin in advanced ovarian carcinoma. Lancet I: 747

    Google Scholar 

  5. Bugat R, Martin P, Namer M, Netter-Pinon G, Belpomme D, Dufour P, Naman H, Pouzin K, Sudre-Pinel MC, Chazard M (1987) A pilot study of carboplatin plus cyclophosphamide and doxorubicin in advanced ovarian carcinoma. Abstract 823, Proceedings of the 4th European Conference on Clinical Oncology, Madrid 216

  6. Canetta R, Rozencweig M, Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 [Suppl A]: 125

    Google Scholar 

  7. Conte PF, Bruzzone M, Chiara S, Rosso R, Giaccone G, Carnino F, Guercio E, Ragni N, Foglia G, Bentivoglio G, Pescetto G, Materman E, Franks C (1988) Carboplatin (JM8), Adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study. Tumori 74: 217

    Google Scholar 

  8. Edmonson JH, McCormack GW, Fleming TR, Cullinan SA, Krook JE, Malkasian GD, Podratz KC, Mailliard JA, Jefferies JA, Barlow JF, Windschitl HE (1985) Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep 69: 1243

    Google Scholar 

  9. Edmonson JH, McCormack GW, Krook JE, Long HJ, Jefferies JA, Richardson RL (1987) Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma. Cancer Treat Rep 71: 199

    Google Scholar 

  10. Edmonson JH, McCormack GM, Wiegand HS, Cullinan SA, Malkasian GD, Krook JE, Stanhope CR, Everson LK, Laurie JA, Kovarik RA (1988) Comparison of cyclophosphamide (Cyclo) + carboplatin (CBDCA) vs Cyclo + cisplatin (CDDP) in stage III and IV ovarian carcinoma. Proc Am Soc Clin Oncol 7: 137

    Google Scholar 

  11. Gruppo Interegionale Cooperative Oncologico Ginecologia (1987) Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet II: 353

    Google Scholar 

  12. Hakes TB (1984) Chemotherapy of advanced ovarian cancer. In: Forastiere AA (Ed) Gynecologic cancer. Churchill Livingstone, New York, p 155

    Google Scholar 

  13. Harding M, Kennedy R, Mill L, MacLean A, Duncan I, Kennedy J, Soukop M, Kaye SB (1988) A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer. Br J Cancer 58: 640

    Google Scholar 

  14. Hillcoat BL, Campbell JJ, Pepperell R, Quinn MA, Bishop JF, Day A (1985) Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 22: 162

    Google Scholar 

  15. Issell BF, Rudolph AR, Louie AC (1984) Etoposide (VP-16-213): an overview. In: Issell BF, Muggia FM, Carter SK (eds) Etoposide (VP-16). Current status and new developments. Academic press, Orlando, p 1

    Google Scholar 

  16. Knox RJ, Friedlos F, Lydall DA, Robert JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence thatcis-diamminedichloroplatinum(II) andcis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972

    Google Scholar 

  17. Kühnle H, Hilfrich J (1985) Chemotherapie des fortgeschrittenen Ovarialkarzinoms. Studien Göttingen-Hannover. Onkologie 8: 374

    Google Scholar 

  18. Kühnle H, Meerpohl HG, Lenaz L, Achterrath W, Pohl J, Roben S, Alfub S, Pfleiderer A, Kuhn W (1988) Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol 7: 137

    Google Scholar 

  19. Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756

    Google Scholar 

  20. Meerpohl HG (1984) Chemotherapie fortgeschrittener epithelialer Ovarialkarzinome. Onkologie 7: 22

    Google Scholar 

  21. Meerpohl HG (1988) Carboplatin (CBDCA) in patients with advanced ovarian cancer: results of two phase II studies. J Cancer Res Clin Oncol 114 [Suppl]: 60

    Google Scholar 

  22. Neijt JP, Ten Bokkel Huinink WW, Burg MEL van der, Oosterom AT van, Willemse PHB, Heintz APM, Lent M van, Trimbos JB, Bouma J, Vermorken JB, Houweligen JC van (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157

    Google Scholar 

  23. Pecorelli S, Bolis G, Vassena L, Epis A, Landoni F, Zanaboni F, Vergadoro F, Favalli G, Gambino A, Marsoni S, Torri W, Jannsen N, Mangioni C (1988) Randomized comparison of cisplatin (P) and carboplatin (C) in advanced ovarian cancer. Proc Am Soc Clin Oncol 7: 136

    Google Scholar 

  24. Piccart MJ, Speyer JL, Wernz JC, Noumoff J, Beller U, Beckman M, Dubin N, Demopoulos R, Muggia F (1987) Advanced ovarian cancer: three-year results of a 6–8 month, 2-drug cisplatin containing regimen. Eur J Cancer Clin Oncol 23: 631

    Google Scholar 

  25. Ross W, Wozniak A, Smallwood S, Yalowich JC (1984) DNA damage by VP-16: mechanism and relationship to cytotoxicity. In: Issell BF, Muggia FM, Carter SK (Eds) Etoposide (VP-16): Current status and new developments. Academic Press, Orlando, p 49

    Google Scholar 

  26. Ten Bokkel Huinink WW, Burg MEL van der, Oosterom AT van, Vermorken JB, Veenhof C, Roosendaal K (1985) A pilot study of CHAC-1. Cancer Treat Rev 12 [Suppl A]: 77

    Google Scholar 

  27. Ten Bokkel Huinink WW, Burg MEL van der, Oosterom AT van, Neijt JP, George M, Guastalla JP, Veenhof CHN, Rotmensz N, Dalesio O, Vermorken JB (1988) Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 15 [Suppl B]: 9

    Google Scholar 

  28. WHO (1979) Handbook for reporting results of cancer treatment. World Health Organisation, Geneva

    Google Scholar 

  29. Wiltshaw E (1985) Ovarian trials at the Royal Marsden. Cancer Treat Rev 12 [Suppl A]: 67

    Google Scholar 

  30. Wiltshaw E, Evans B, Harland S (1985) Phase III randomised trial of cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV. Proc Am Soc Clin Oncol 4: 121

    Google Scholar 

  31. Wiltshaw E, Smales E, Gallagher CJ, Staffurth J (1986) Carboplatin (Paraplatin) in ovarian cancer. Lectures and Symposia of the 14th International Cancer Congress, Budapest, 1986, p 3

Download references

Author information

Affiliations

  1. Klinikum Grosshadern der Universität, Frauenklinik Marchioninistrasse 15, W-8000, München 70, Germany

    Wolfgang Eiermann & Hermann Hepp

  2. Bristol-Myers International group, 345 Park Avenue, 10154, New York, N. Y., USA

    Wolf Achterrath & Luigi Lenaz

Authors
  1. Wolfgang Eiermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolf Achterrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luigi Lenaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hermann Hepp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eiermann, W., Achterrath, W., Lenaz, L. et al. Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Cancer Chemother. Pharmacol. 27, 389–393 (1991). https://doi.org/10.1007/BF00688863

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00688863

Keywords

  • Carcinoma
  • Bone Marrow
  • Ovarian Cancer
  • Cancer Research
  • Pilot Study